GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets.
GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a novel viral neuraminidase (sialidase) inhibitor which, following intranasal administration in ferrets, is at least 100 to 1,000 times more effective than ribavirin and amantadine against influenza A and B viruses. It retains its activity even when treatments are delayed until 24 h postinfection and has no effect on the serum antibody response to infection.
Ryan
D M
DM
Glaxo Wellcome Research and Development Limited, Stevenage, United Kingdom.
Ticehurst
J
J
Dempsey
M H
MH
D000281:Administration, Intranasal; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005289:Ferrets; D006146:Guanidines; D009980:Influenza A virus / Q000187:drug effects*; D009981:Influenza B virus / Q000187:drug effects*; D009976:Orthomyxoviridae Infections / Q000188:drug therapy* / Q000517:prevention & control / Q000821:virology; D011714:Pyrans; D012794:Sialic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D053243:Zanamivir
D000998:Antiviral Agents; D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; D053243:Zanamivir